The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

AIDS

Volumn 19, Issue 13, 2005, Pages 1393-1399

  Winston, Alan ^a   Hales, Gill ^a   Amin, Janaki ^a   Van Schaick, Erno ^b   Cooper, David A ^a   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Virco BVBA   (Belgium)

Author keywords

Boosted protease inhibitor therapy; HIV disease; HIV drug resistance; Inhibitory quotient; Pharmacokinetics; Salvage therapy

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 29144452574     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000181009.77632.36     Document Type: Article

References (24)

1. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998; 279: 1984-1991.
2. Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000; 30:313-318.
3. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 (Suppl 2):S151-S159.
4. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000; 40:649-674.
5. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
6. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
7. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13: F17-F21.
8. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19:708-712.
9. Dumon C, Solas C, Thuret I, Chambost H, Lacarelle B, Michel G, et al. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit 2000; 22:402-408.
10. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 1997; 11:F95-F99.
11. Ellner PD, Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 1981; 246:1575-1578.
12. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47:594-600.
13. Gonzalez de Requena D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retrovir 2004; 20:275-278.
14. Casado JL, Moreno A, Sabido R, Marti-Belda P, Antela A, Dronda F, et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003; 17:262-264.
15. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002; 46:3907-3916.
16. Flexner C. IQs, VIQs, and NIQs: are we smart yet? Hopkins HIV Rep 2002; 14:6-7.
17. Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, et al. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritoanvir-containing regimen. Antiviral Ther 2004; 9:537-543.
18. Emery S, Birch C, Crowe S, Hoy J, Workman C, Kellerher A, et al. CREST-A Randomized Comparison of Genotype and Genotype Plus Virtual Phenotype (VircoGen II). Paper presented at 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003 [poster 592].
19. Montaner J, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 2001; 357:1438-1440.
20. Bacheler LT, Winters B, Nauwelaers D, Rinehart A, McGregor M, Harrigan R, et al. Estimation of phenotypic clinical cutoffs for VirtualPhenotype through meta analyses of clinical trial and cohort data. Antiviral Ther 2004; 9(S154) [abstract 138].
21. Hellinger J, Cohen C, Morris AB, Hall SS, Jackson-Pope L, de Caprariis PJ, et al. A pilot study of saquinavir-SGC and lopinavir/ritonavir twice daily in protease inhibitor naive HIV-positive individuals: protease inhibitor concentrations and week 48 results. Paper presented at Second IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003 [abstract B10347].
22. Hellinger J, Morris A, Piscitelli S, Gordon D, Foy K, Jackson-Pope L, et al. Pilot study of saquinavir-SGC 1000 mg twice daily and lopinavir/ritonavir in protease inhibitor-experienced HIV+ individuals: Dose escalation and combined normalized inhibitory quotient. Paper presented at Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002 [abstract 451-W].
23. Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, et al. Salvage therapy with lopinavir/ritonavir, amprenavir + an additional boost with ritonavir: 1-year results of Puzzle 1-ANRS 104 study. Paper presented at Second IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003 [abstract 585].
24. Phillips E, Tseng A, Walker S, Loutfy M, Walmsley S, Tailor S, et al. The use of virtual inhibitory quotient (VIQ) in antiretroviral (ART)-experienced patients taking amprenavir/lopinavir combinations. Paper presented at Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002 [abstract 130].